GILD
Price
$113.00
Change
+$0.44 (+0.39%)
Updated
Aug 29, 04:59 PM (EDT)
Capitalization
139.67B
55 days until earnings call
GRFS
Price
$9.93
Change
+$0.06 (+0.61%)
Updated
Aug 29, 04:01 PM (EDT)
Capitalization
8.55B
69 days until earnings call
Interact to see
Advertisement

GILD vs GRFS

Header iconGILD vs GRFS Comparison
Open Charts GILD vs GRFSBanner chart's image
Gilead Sciences
Price$113.00
Change+$0.44 (+0.39%)
Volume$118.53K
Capitalization139.67B
Grifols SA
Price$9.93
Change+$0.06 (+0.61%)
Volume$100
Capitalization8.55B
GILD vs GRFS Comparison Chart in %
Loading...
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GILD vs. GRFS commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GILD is a StrongBuy and GRFS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (GILD: $112.56 vs. GRFS: $9.87)
Brand notoriety: GILD: Notable vs. GRFS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GILD: 66% vs. GRFS: 73%
Market capitalization -- GILD: $139.67B vs. GRFS: $8.55B
GILD [@Pharmaceuticals: Major] is valued at $139.67B. GRFS’s [@Pharmaceuticals: Major] market capitalization is $8.55B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $656.17B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $88.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GILD’s FA Score shows that 3 FA rating(s) are green whileGRFS’s FA Score has 1 green FA rating(s).

  • GILD’s FA Score: 3 green, 2 red.
  • GRFS’s FA Score: 1 green, 4 red.
According to our system of comparison, GILD is a better buy in the long-term than GRFS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GILD’s TA Score shows that 3 TA indicator(s) are bullish while GRFS’s TA Score has 3 bullish TA indicator(s).

  • GILD’s TA Score: 3 bullish, 5 bearish.
  • GRFS’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, GILD is a better buy in the short-term than GRFS.

Price Growth

GILD (@Pharmaceuticals: Major) experienced а -3.08% price change this week, while GRFS (@Pharmaceuticals: Major) price change was -2.08% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.84%. For the same industry, the average monthly price growth was +1.29%, and the average quarterly price growth was +11.90%.

Reported Earning Dates

GILD is expected to report earnings on Oct 23, 2025.

GRFS is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.84% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
GILD($140B) has a higher market cap than GRFS($8.55B). GILD has higher P/E ratio than GRFS: GILD (22.33) vs GRFS (19.18). GRFS YTD gains are higher at: 37.180 vs. GILD (23.584). GILD has higher annual earnings (EBITDA): 11B vs. GRFS (1.62B). GILD has more cash in the bank: 5.21B vs. GRFS (566M). GRFS has less debt than GILD: GRFS (8.82B) vs GILD (24.9B). GILD has higher revenues than GRFS: GILD (28.9B) vs GRFS (7.45B).
GILDGRFSGILD / GRFS
Capitalization140B8.55B1,637%
EBITDA11B1.62B680%
Gain YTD23.58437.18063%
P/E Ratio22.3319.18116%
Revenue28.9B7.45B388%
Total Cash5.21B566M921%
Total Debt24.9B8.82B282%
FUNDAMENTALS RATINGS
GILD vs GRFS: Fundamental Ratings
GILD
GRFS
OUTLOOK RATING
1..100
6373
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
22
Undervalued
PROFIT vs RISK RATING
1..100
15100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
2847
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
1650

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GILD's Valuation (15) in the Biotechnology industry is in the same range as GRFS (22) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to GRFS’s over the last 12 months.

GILD's Profit vs Risk Rating (15) in the Biotechnology industry is significantly better than the same rating for GRFS (100) in the Pharmaceuticals Major industry. This means that GILD’s stock grew significantly faster than GRFS’s over the last 12 months.

GILD's SMR Rating (100) in the Biotechnology industry is in the same range as GRFS (100) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to GRFS’s over the last 12 months.

GILD's Price Growth Rating (28) in the Biotechnology industry is in the same range as GRFS (47) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to GRFS’s over the last 12 months.

GILD's P/E Growth Rating (100) in the Biotechnology industry is in the same range as GRFS (100) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to GRFS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GILDGRFS
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 2 days ago
71%
Momentum
ODDS (%)
Bearish Trend 2 days ago
48%
Bearish Trend 2 days ago
64%
MACD
ODDS (%)
Bearish Trend 2 days ago
34%
Bearish Trend 2 days ago
70%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
46%
Bearish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
45%
Bearish Trend 2 days ago
71%
Advances
ODDS (%)
Bullish Trend 19 days ago
59%
Bullish Trend 16 days ago
73%
Declines
ODDS (%)
Bearish Trend 2 days ago
48%
Bearish Trend 9 days ago
74%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
43%
Bearish Trend 2 days ago
70%
Aroon
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
75%
View a ticker or compare two or three
Interact to see
Advertisement
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPMO117.800.52
+0.44%
Invesco S&P 500® Momentum ETF
WBIG22.57-0.04
-0.16%
WBI BullBear Yield 3000 ETF
BCOR31.67-0.09
-0.30%
Grayscale Bitcoin Adopters ETF
SMDV68.59-0.35
-0.51%
ProShares Russell 2000 Dividend Growers
UAE19.53-0.15
-0.76%
iShares MSCI UAE ETF

GRFS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GRFS has been closely correlated with GIKLY. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if GRFS jumps, then GIKLY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRFS
1D Price
Change %
GRFS100%
+0.71%
GIKLY - GRFS
68%
Closely correlated
N/A
GIFOF - GRFS
37%
Loosely correlated
N/A
PFE - GRFS
28%
Poorly correlated
-1.87%
BIIB - GRFS
27%
Poorly correlated
-2.72%
GILD - GRFS
26%
Poorly correlated
-1.19%
More